Immunotherapy and radiation with chemotherapy for untreated stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with chemotherapy (SOX) and radiation for stomach cancer that hasn't been treated before. The goal is to see if this approach can shrink tumors and help you live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have stomach cancer or cancer at the junction of the stomach and esophagus that has not spread beyond where it started or has spread to other parts of the body (metastatic).
- You must not have had previous chemotherapy or other drug treatment for this advanced cancer. If you had chemo or radiation before surgery and then the cancer came back, at least 6 months must have passed since that treatment.
- Your cancer must be HER2-negative, which means a lab test shows a low or no amount of a certain protein that helps cancer grow.
- You must have at least one tumor that can be measured and is suitable for radiation therapy.
- You must be in generally good health, able to perform daily activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer who have not had prior treatment. It aims to see if this combination can shrink tumors and help people live longer.
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs before surgery for people with resectable gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with a chemotherapy drug (albumin-bound paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow cancer growth.
This trial tests combining an immunotherapy drug (sintilimab) with a targeted therapy (ramucirumab) and chemotherapy (paclitaxel) for stomach cancer that came back soon after surgery and chemotherapy. The goal is to see if this combined approach can help control the cancer and prolong life.
This trial studies a new immunotherapy drug (SHR-1701) combined with standard chemoradiotherapy for people with advanced stomach or esophagus cancer that cannot be surgically removed. The goal is to see if adding this immune treatment helps control the tumor better than standard treatments alone.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
Hear when a new Gastric Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.